Kodiak Sciences Inc. Share Price & Technical Analysis
KOD · $33.87 (+1.96%)
Healthcare / Biotechnology
$33.87
+1.96%
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in …
Price chart
Seasonality
Jun has 3 positive and 2 negative years (last 5 years shown)
-5% return in Jun, -1% avg return in past 3 year Jun month.
33% return in 2026, 122% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -18% | 16% | 46% | 9% | -15% | -5% | – | – | – | – | – | – | 33% |
| 25 | -35% | -34% | -33% | 57% | -23% | 9% | 78% | 43% | 84% | 15% | 27% | 26% | 214% |
| 24 | 33% | 46% | -12% | -41% | 0% | -28% | 21% | -14% | 4% | 46% | 72% | 46% | 174% |
| 23 | 13% | -20% | -6% | -24% | 34% | 15% | -57% | -27% | -18% | -17% | 60% | 25% | -21% |
| 22 | -31% | -86% | -10% | -23% | 20% | 6% | 29% | 1% | -22% | -9% | 1% | -3% | -128% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.15B
P/E ratio
—
52W high
$47.84
52W low
$3.43
Volume
9,27,893
Beta
2.32
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Kodiak Sciences Inc. share price today?
- Kodiak Sciences Inc. (KOD) last traded around $33.87 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KOD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KOD. Download the app for real-time alerts.
- How can I analyze Kodiak Sciences Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.